Literature DB >> 11595452

Ethanol gastric lesion aggravated by lung injury in rat. Therapy effect of antiulcer agents.

D Stancic-Rokotov1, P Sikiric, S Seiwerth, Z Slobodnjak, J Aralica, G Aralica, D Perovic, T Anic, I Zoricic, G Buljat, I Prkacin, M Gjurasin, R Rucman, M Petek, B Turkovic, Z Ivasovic, V Jagic, M Staresinic, A Boban-Blagaic.   

Abstract

Hemorrhagic mucosal lesions in the stomach in the rat induced by an intragastrical application of 1 ml of 50 or 75% ethanol were aggravated by preceding lung damage provoked by an intratracheal instillation of pyrogen-free saline or HCl (pH 1.75) or 50-h exposure to 100% oxygen. Due to the particular preceding aggravating circumstances, these lesions were taken to be of a special kind, rather than ordinary. So far, it is not known whether and how antiulcer agents may influence these lesions. Rats received an intratracheal (i.t.) HCl instillation [1.5 ml/kg HCl (pH 1.75)] (lung-lesion), and an intragastric instillation of 96% ethanol (gastric lesion; 1 ml/rat, 24 h after i.t. HCl instillation), and were sacrificed 1 h after ethanol. Basically, in lung injured rats, the subsequent ethanol-gastric lesion was markedly aggravated. This aggravation, however, in turn, did not affect the severity of the lung lesions in the further period, at least for a 1-h observation. Taking intratracheal HCl-instillation as time 0, a gastric pentadecapeptide, GEPPPGKPADDAGLV, M.W.1419, coded BPC 157 (PL-10, PLD-116; 10 microg, 10 ng, 10 pg), ranitidine (10 mg), atropine (10 mg), omeprazole (10 mg), were given [/kg, intraperitoneally (i.p.)] (1) once, only prophylactically [as a pre-treatment (at -1 h), or as a co-treatment (at 0)], or only therapeutically (at +18 h or +24 h); (2) repeatedly, combining prophylactic/therapeutic regimens [(-1 h)+(+24 h) or (0)+(+24 h)], or therapeutic/therapeutic regimens [(+18 h)+(+24 h)]. In general, the antiulcer agents did protect against ethanol gastric lesions regardless of the presence of the severe lung injury, in all of the used regimens. Of note, combining their prophylactic and salutary regimens (at -1 h/+24 h, or at 0/+24 h) may increase the antiulcer potential, and the effect that had been not seen already with single application, became prominent after repeated treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595452     DOI: 10.1016/s0928-4257(01)00040-7

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  6 in total

1.  Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats.

Authors:  Ivan Maria Smoday; Igor Petrovic; Luka Kalogjera; Hrvoje Vranes; Helena Zizek; Ivan Krezic; Slaven Gojkovic; Ivan Skorak; Klaudija Hriberski; Ivan Brizic; Milovan Kubat; Sanja Strbe; Ivan Barisic; Marija Sola; Eva Lovric; Marin Lozic; Alenka Boban Blagaic; Anita Skrtic; Sven Seiwerth; Predrag Sikiric
Journal:  Biomedicines       Date:  2022-06-01

2.  Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats.

Authors:  Xiao-Chang Xue; Yong-Jie Wu; Ming-Tang Gao; Wen-Guang Li; Ning Zhao; Zeng-Lu Wang; Chun-Jie Bao; Zhen Yan; Ying-Qi Zhang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

3.  Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion.

Authors:  Marijan Kolovrat; Slaven Gojkovic; Ivan Krezic; Dominik Malekinusic; Borna Vrdoljak; Katarina Kasnik Kovac; Tamara Kralj; Domagoj Drmic; Ivan Barisic; Katarina Horvat Pavlov; Andreja Petrovic; Antonija Duzel; Mario Knezevic; Ivan Mirkovic; Antonio Kokot; Alenka Boban Blagaic; Sven Seiwerth; Predrag Sikiric
Journal:  World J Hepatol       Date:  2020-05-27

4.  Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.

Authors:  Marijan Tepes; Slaven Gojkovic; Ivan Krezic; Helena Zizek; Hrvoje Vranes; Zrinko Madzar; Goran Santak; Lovorka Batelja; Marija Milavic; Suncana Sikiric; Ivica Kocman; Karol Simonji; Mariam Samara; Mario Knezevic; Ivan Barisic; Eva Lovric; Sanja Strbe; Antonio Kokot; Ivica Sjekavica; Toni Kolak; Anita Skrtic; Sven Seiwerth; Alenka Boban Blagaic; Predrag Sikiric
Journal:  Front Pharmacol       Date:  2021-12-13       Impact factor: 5.810

5.  Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: Gastric Pentadecapeptide BPC 157 Therapy Counteracts Multiple Organ Dysfunction Syndrome; Intracranial, Portal, and Caval Hypertension; and Aortal Hypotension.

Authors:  Mario Knezevic; Slaven Gojkovic; Ivan Krezic; Helena Zizek; Dominik Malekinusic; Borna Vrdoljak; Hrvoje Vranes; Tamara Knezevic; Ivan Barisic; Katarina Horvat Pavlov; Domagoj Drmic; Miro Staroveski; Antonija Djuzel; Zoran Rajkovic; Toni Kolak; Ivica Kocman; Eva Lovric; Marija Milavic; Suncana Sikiric; Ante Tvrdeic; Leonardo Patrlj; Sanja Strbe; Antonio Kokot; Alenka Boban Blagaic; Anita Skrtic; Sven Seiwerth; Predrag Sikiric
Journal:  Biomedicines       Date:  2021-05-26

6.  Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats.

Authors:  Slaven Gojkovic; Ivan Krezic; Borna Vrdoljak; Dominik Malekinusic; Ivan Barisic; Andreja Petrovic; Katarina Horvat Pavlov; Marijan Kolovrat; Antonija Duzel; Mario Knezevic; Katarina Kasnik Kovac; Domagoj Drmic; Lovorka Batelja Vuletic; Antonio Kokot; Alenka Boban Blagaic; Sven Seiwerth; Predrag Sikiric
Journal:  World J Gastrointest Pathophysiol       Date:  2020-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.